![](https://investorshub.advfn.com/uicon/40490.png?cb=1674047870)
Tuesday, April 25, 2023 10:30:16 AM
Recent VIRI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 02:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:30:13 PM
- Virios Therapeutics Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 01:15:00 PM
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 01:41:56 PM
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center • GlobeNewswire Inc. • 07/23/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 01:15:20 PM
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/22/2024 05:30:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/20/2024 08:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:28:00 PM
- Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/20/2024 12:53:09 AM
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/17/2024 08:10:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/17/2024 08:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 02:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:01:31 PM
- Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:25:53 PM
- Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 01:15:00 PM
- Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID • GlobeNewswire Inc. • 03/26/2024 01:15:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/08/2024 10:00:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/01/2024 02:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 02:25:17 PM
- Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 02:15:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 06:14:56 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM